PDCD1 and neoplasm: These results indicate that cytotoxic T-cells, in response to SMC and anti-PD-1 treatment, may lead to enhanced tumour cell death due to the increased production of GrzB and TNF-α, pro-death factors that induce tumour cell death due to the antagonism of the IAPs.